Get the Stockscreener App
7.3676
1.24%
-0.1224
Aura Biosciences Inc stock is traded at $7.3676, with a volume of 52,670.
It is down -1.24% in the last 24 hours and down -6.84% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$7.49
Open:
$7.5
24h Volume:
52,670
Relative Volume:
0.35
Market Cap:
$373.14M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-3.8373
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
-0.98%
1M Performance:
-6.84%
6M Performance:
-26.54%
1Y Performance:
-6.60%
1-Day Range:
$7.35
$7.51
1-Week Range:
$7.05
$7.56
52-Week Range:
$6.63
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
7.35 | 373.14M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.02 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
686.39 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.20 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.49 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.10 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
Tarsus Pharmaceuticals (NASDAQ:TARS) & Aura Biosciences (NASDAQ:AURA) Critical Survey - Defense World
H.C. Wainwright maintains $22 target on Aura Biosciences stock By Investing.com - Investing.com UK
Buy Rating for Aura Biosciences Driven by Promising Bel-sar Developments and Market Potential - TipRanks
Promising Developments in Aura Biosciences Inc’s Clinical Trials Lead to Buy Rating - TipRanks
Aura Biosciences to present new bladder cancer study data - Investing.com
Aura Biosciences to Present Phase 1 Data on Bel-sar and Host Virtual Urologic Oncology Investor Event at 40th Annual EAU Congress - Nasdaq
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress - GlobeNewswire
Will Aura's Bladder Cancer Treatment Change Patient Outcomes? New Data Coming in 2025 - StockTitan
How to Take Advantage of moves in (AURA) - Stock Traders Daily
Syndax Announces Participation in March Investor Conferences - The Manila Times
Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
How Will Aura Biosciences Address Investors at Two Major Healthcare Conferences Next Month? - StockTitan
Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00 - Defense World
Aura Biosciences CEO sells shares worth $156,795 - Investing.com India
Aura Biosciences chief medical officer sells $19,638 in stock By Investing.com - Investing.com South Africa
Aura Biosciences CEO sells shares worth $156,795 By Investing.com - Investing.com Nigeria
Aura Biosciences CTO sells shares for $16,670 By Investing.com - Investing.com South Africa
Aura Biosciences senior VP sells $10,881 in stock to cover taxes - Investing.com
Aura Biosciences chief medical officer sells $19,638 in stock - Investing.com
Aura Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView
Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs Market 2034: - openPR
Aura Biosciences CTO sells shares for $16,670 - Investing.com
Healthy Upside Potential: Aura Biosciences Inc (AURA) - SETE News
How To Trade (AURA) - Stock Traders Daily
FY2025 Earnings Estimate for AURA Issued By Leerink Partnrs - MarketBeat
Ocular melanoma Market Expected to Experience Major Growth - openPR
AURAAura Energy Limited September 2020 Quarterly Report (5044E) - br.ADVFN.com
What is Leerink Partnrs’ Estimate for AURA FY2025 Earnings? - Defense World
Research Analysts Issue Forecasts for AURA Q1 Earnings - Defense World
CV Sciences Unveils New Aura Collection THC Fizz Tablets - Yahoo Finance
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat
Aura Biosciences (NASDAQ:AURA) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
Lifesci Capital Upgrades Aura Biosciences (NASDAQ:AURA) to Strong-Buy - Defense World
Investing in Aura Minerals (TSE:ORA) five years ago would have delivered you a 822% gain - Yahoo Finance
JPMorgan Chase & Co. Grows Holdings in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Financial Analysis: New Concept Energy (NYSE:GBR) versus Riley Exploration Permian (NYSE:REPX) - Defense World
Waystar (NASDAQ:WAY) & Verint Systems (NASDAQ:VRNT) Critical Review - Defense World
Head-To-Head Contrast: Yara International ASA (OTCMKTS:YARIY) vs. Ero Copper (NYSE:ERO) - Defense World
Analysts Set Aura Biosciences, Inc. (NASDAQ:AURA) PT at $23.00 - Defense World
Regency Capital Management Inc. DE Sells 57,887 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average Target Price from Brokerages - MarketBeat
What is Lifesci Capital’s Estimate for AURA FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for AURA Issued By Lifesci Capital - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics - Barchart
This Insider Has Just Sold Shares In Aura Biosciences - Simply Wall St
Where are the Opportunities in (AURA) - Stock Traders Daily
Non Muscle Invasive Bladder Cancer Pipeline 2024: MOA, ROA, - openPR
Aura Biosciences VP Amy Elazzouzi sells $7,679 in stock - MSN
Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $122,374.85 in Stock - MarketBeat
Aura Biosciences CEO Elisabet de los Pinos sells shares worth $122,381 - MSN
Aura Biosciences VP Amy Elazzouzi sells $7,679 in stock By Investing.com - Investing.com Australia
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):